However, Tamoxifen and Aromatase inhibitors (estrogen signaling inhibitor agents) have not been reported in the literature, due to the low expression of ER in Ductal Carcinoma of the Salivary Gland. This evidence concerns the gene CYP19A1 and breast ductal adenocarcinoma.